Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs

PARP1 is the target of clinically approved anti-cancer drugs whose in vivo efficacy has been hard to predict. Here the authors show how an altered active site formed between PARP1 and Histone PARylation Factor 1 (HPF1) changes the efficacy of some of these inhibitors.

Guardado en:

Detalles Bibliográficos
Autores principales:	Johannes Rudolph, Genevieve Roberts, Karolin Luger
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/33d6d10fa6924050954dfbd2aa320cee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33d6d10fa6924050954dfbd2aa320cee
record_format	dspace
spelling	oai:doaj.org-article:33d6d10fa6924050954dfbd2aa320cee2021-12-02T14:06:23ZHistone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs10.1038/s41467-021-20998-82041-1723https://doaj.org/article/33d6d10fa6924050954dfbd2aa320cee2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-20998-8https://doaj.org/toc/2041-1723PARP1 is the target of clinically approved anti-cancer drugs whose in vivo efficacy has been hard to predict. Here the authors show how an altered active site formed between PARP1 and Histone PARylation Factor 1 (HPF1) changes the efficacy of some of these inhibitors.Johannes RudolphGenevieve RobertsKarolin LugerNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Johannes Rudolph Genevieve Roberts Karolin Luger Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
description	PARP1 is the target of clinically approved anti-cancer drugs whose in vivo efficacy has been hard to predict. Here the authors show how an altered active site formed between PARP1 and Histone PARylation Factor 1 (HPF1) changes the efficacy of some of these inhibitors.
format	article
author	Johannes Rudolph Genevieve Roberts Karolin Luger
author_facet	Johannes Rudolph Genevieve Roberts Karolin Luger
author_sort	Johannes Rudolph
title	Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
title_short	Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
title_full	Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
title_fullStr	Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
title_full_unstemmed	Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
title_sort	histone parylation factor 1 contributes to the inhibition of parp1 by cancer drugs
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/33d6d10fa6924050954dfbd2aa320cee
work_keys_str_mv	AT johannesrudolph histoneparylationfactor1contributestotheinhibitionofparp1bycancerdrugs AT genevieveroberts histoneparylationfactor1contributestotheinhibitionofparp1bycancerdrugs AT karolinluger histoneparylationfactor1contributestotheinhibitionofparp1bycancerdrugs
_version_	1718392012208603136

Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs

Ejemplares similares